Border

AbbVie signs drug pricing deal

Border

AbbVie has struck a new drug pricing agreement with the White House that aligns with the administration’s most-favored-nation pricing initiative. Under the deal, the company will lower prices on select medicines for Medicaid and expand direct-to-patient offerings through the TrumpRx platform, while committing to $100 billion in U.S. research, development and capital investment over the next decade. In return, AbbVie earns exemptions from tariffs and future pricing mandates — a significant regulatory reprieve amid broader industry negotiations on drug costs.

Click here to read the entire article.

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

The Skills Employees Need to Succeed in the Age of AI

◆

Artificial intelligence is changing the workplace, but the skills employees need in the age of AI are not necessarily new.…

#455: Interview Questions for Hiring Managers: How to Identify the Right Candidate

◆

An effective interview is about more than confirming what’s already listed on a candidate’s resume. It’s an opportunity for hiring…

Scroll to Top